CLINICAL TRIALS PROFILE FOR HALOPERIDOL
✉ Email this page to a colleague
All Clinical Trials for HALOPERIDOL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000179 ↗ | Agitation in Alzheimer's Disease | Completed | National Institute on Aging (NIA) | Phase 3 | 1969-12-31 | Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug approach, has been effective in reducing signs of agitation. Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with funding from the National Institute on Aging, is conducting an agitation treatment program at 21 sites in 16 States. This study will assess which of the above treatments is most effective. |
| NCT00000274 ↗ | Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9 | Completed | New York State Psychiatric Institute | Phase 2 | 1997-03-01 | The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness. |
| NCT00000274 ↗ | Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1997-03-01 | The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness. |
| NCT00000373 ↗ | Treatment of Obsessive-Compulsive Disorder | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 1992-09-01 | The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for HALOPERIDOL
Condition Name
Clinical Trial Locations for HALOPERIDOL
Trials by Country
Clinical Trial Progress for HALOPERIDOL
Clinical Trial Phase
Clinical Trial Sponsors for HALOPERIDOL
Sponsor Name
